CLL14 - study of GDC-0199 in CLL

• Research type

  Research Study

• Full title

  A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND GDC-0199 (ABT-199) VERSUS OBINUTUZUMAB AND CHLORAMBUCIL IN PREVIOUSLY UNTREATED PATIENTS WITH CLL AND COEXISTING MEDICAL CONDITIONS

• IRAS ID

  162273

• Contact name

  Shankara Paneesha

• Contact email

  shankara.paneesha@heartofengland.nhs.uk

• Sponsor organisation

  F. Hoffmann-La Roche Ltd

• Eudract number

  2014-001810-24

• Clinicaltrials.gov Identifier

  NCT02242942

• Duration of Study in the UK

  6 years, 4 months, 30 days

• Research summary

  Please see http://www.roche-trials.com for full details of this study. Alternatively, visit ClinicalTrials.gov and use the identifier NCT02242942

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  15/EM/0069

• Date of REC Opinion

  16 Feb 2015

• REC opinion

  Further Information Favourable Opinion